TY - JOUR
T1 - Gabapentin for smoking cessation
T2 - A preliminary investigation of efficacy
AU - Sood, Amit
AU - Ebbert, Jon O.
AU - Schroeder, Darrell R.
AU - Croghan, Ivana T.
AU - Sood, Richa
AU - Weg, Mark W.Vander
AU - Wong, Gilbert Y.
AU - Hays, J. Taylor
PY - 2007/2
Y1 - 2007/2
N2 - Gabapentin affects the glutamate and gamma amino butyric acid (GABA) neurotransmitters through which it may facilitate smoking abstinence. To obtain preliminary estimates of efficacy of gabapentin for smoking cessation, we conducted a single-arm, open-label study of gabapentin, 1,800-mg/day administered in three equal divided doses for 8 weeks. A total of 50 adult smokers were enrolled. All participants received a brief behavioral intervention at each medication visit. A total of 37 participants completed all follow-up assessments. At end-of-treatment the biochemically confirmed point-prevalence and prolonged smoking abstinence rates were 28% (95% CI=16%-42%) and 24% (95% CI=13%-38%), respectively. At 6 months, the biochemically confirmed point-prevalence and prolonged smoking abstinence rates were 20% (95% CI=10%-34%) and 16% (95% CI=7%-29%), respectively. Among subjects who continued to smoke and completed the follow-up assessments, the reported number of cigarettes smoked per day (mean±standard deviation) was significantly less than at baseline: -10.0±8.2 (p<.001). Adverse effects were minor and well tolerated. Our results suggest that gabapentin may increase smoking abstinence. An adequately powered randomized clinical trial assessing different doses of this drug against a placebo would be the reasonable next step.
AB - Gabapentin affects the glutamate and gamma amino butyric acid (GABA) neurotransmitters through which it may facilitate smoking abstinence. To obtain preliminary estimates of efficacy of gabapentin for smoking cessation, we conducted a single-arm, open-label study of gabapentin, 1,800-mg/day administered in three equal divided doses for 8 weeks. A total of 50 adult smokers were enrolled. All participants received a brief behavioral intervention at each medication visit. A total of 37 participants completed all follow-up assessments. At end-of-treatment the biochemically confirmed point-prevalence and prolonged smoking abstinence rates were 28% (95% CI=16%-42%) and 24% (95% CI=13%-38%), respectively. At 6 months, the biochemically confirmed point-prevalence and prolonged smoking abstinence rates were 20% (95% CI=10%-34%) and 16% (95% CI=7%-29%), respectively. Among subjects who continued to smoke and completed the follow-up assessments, the reported number of cigarettes smoked per day (mean±standard deviation) was significantly less than at baseline: -10.0±8.2 (p<.001). Adverse effects were minor and well tolerated. Our results suggest that gabapentin may increase smoking abstinence. An adequately powered randomized clinical trial assessing different doses of this drug against a placebo would be the reasonable next step.
UR - http://www.scopus.com/inward/record.url?scp=34047196330&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34047196330&partnerID=8YFLogxK
U2 - 10.1080/14622200601080307
DO - 10.1080/14622200601080307
M3 - Article
C2 - 17365760
AN - SCOPUS:34047196330
SN - 1462-2203
VL - 9
SP - 291
EP - 298
JO - Nicotine and Tobacco Research
JF - Nicotine and Tobacco Research
IS - 2
ER -